

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

# HIV MONITORING QUARTERLY REPORT FOR BRITISH COLUMBIA

THIRD QUARTER 2016

















# Foreword

As part of the BC Centre for Excellence (BC-CFE) in HIV/AIDS's mandate to evaluate the outcomes of STOP HIV/AIDS programming in BC, we have developed quarterly HIV/AIDS monitoring reports. These reports provide up-to-date data on a variety of key HIV-related surveillance and treatment indicators. Selection of these indicators was achieved through a collaborative process with various Health Authority (HA) representatives. There are six reports in total, one for each HA and one for the province of BC as a whole. In addition, there is a technical report which explains how each HIV indicator is calculated. Data used in these reports come from the British Columbia Centre for Disease Control (BCCDC), MSP billings, hospitalization data from the Discharge Abstract Database, the Sunquest Laboratory database at the Provincial Public Health Microbiology and Reference Laboratory, Providence Health Care laboratory, BC Vital Statistics, and the BC-CFE Drug Treatment Program (DTP) Database.

The objectives of these reports are to:

- 1. Provide timely HA-specific information on key HIV indicators which will guide and inform HIV leaders and innovators in the development of future HIV interventions and programs which will ultimately lead to decreasing the burden of HIV in BC. The indicators will reflect ongoing or past successful public health interventions and highlight areas in the HIV care spectrum which require further attention and support.
- 2. Highlight limitations in our current data due to incomplete or time lagged data and to develop future strategies to improve complete and timely data capture.

These reports are produced for the benefit of individual HA's. As such, we are enthusiastic about your involvement and cooperation regarding the development of these monitoring reports. Please forward your comments and queries to Irene Day, Director of Operations at the BC-CFE at iday@cfenet.ubc.ca.

# List of Indicators

Indicator 1. HIV Testing Episodes

Indicator 2. HIV Testing Rate

Indicator 3. New HIV Diagnoses

Indicator 4. Stage of HIV Infection at Diagnosis

Indicator 5. HIV Cascade of Care

Indicator 6. Programmatic Compliance Score (PCS)

Indicator 7. New Antiretroviral Therapy Starts

Indicator 8. CD4 Cell Count at ART Initiation

Indicator 9. Active and Inactive Drug Treatment Program (DTP) Participants

Indicator 10. Antiretroviral Adherence

Indicator 11. Resistance Testing and Results

Indicator 12. AIDS-Defining Illness

Indicator 13. HIV-Related Mortality

# Table of Contents

#### Acknowledgements and Contributions

#### BC Provincial STOP Program:

#### A Note on Monitoring and Interpreting HIV Indicators

Indicator 1	HIV Testing Episodes All HIV Testing Episodes reflect non-prenatal tests. All prenatal tests have been removed.
Figure 1.1	HIV Test Episodes for BC, 2011 Q4–2016 Q3
Figure 1.2	HIV Test Episodes for BC by Gender, 2011 Q4–2016 Q3
Figure 1.3	HIV Test Episodes for BC by Age Category, 2011 Q4–2016 Q3
Figure 1.4	Point-of-Care HIV Tests for BC, 2011 Q4-2016 Q3
Figure 1.5	HIV Test Episodes by Health Authority for BC, 2011 Q4–2016 Q3
Figure 1.6	HIV Test Episodes for Non-Prenatal Females in BC by Health Authority, 2011 Q4–2016 Q3
Figure 1.7	Hıv Test Episodes for Males in вс by Health Authority, 2011 Q4–2016 Q3
Indicator 2	HIV Testing Rates All HIV Testing Rates reflect non-prenatal tests. All prenatal tests have been removed.
Figure 2.1	Rate of HIV Testing for BC and Health Authorities, 2009–2015
Figure 2.2	Rate of HIV Testing for BC by Gender, 2009–2015
Figure 2.3	Rate of HIV Testing for BC by Age Category, 2009–2015
Indicator 3	New HIV Diagnoses
Figure 3.1	New HIV Diagnoses for BC, 2011 Q4–2016 Q3
Figure 3.2	New HIV Diagnoses for BC by Gender, 2011 Q4–2016 Q3
Figure 3.3	New HIV Diagnoses for BC by Age Category, 2011 Q4-2016 Q3
Figure 3.4	New HIV Diagnoses for BC by Exposure Category, 2011 Q1–2015 Q2
Figure 3.5	New HIV Diagnoses for BC by Health Authority, 2011 Q4–2016 Q3
Indicator 4	<b>Stage of HIV Infection at Diagnosis</b> Stage definitions have been altered to remove AIDS diagnosis data. Individuals previously classified as Stage 3 have been re-classified based on CD4 cell count.
Table 1	Staging Classifications of Infection at Time of HIV Diagnosis Based on CDC HIV Surveillance Case Definitions
Figure 4.1	Stage of HIV Infection at Diagnosis for BC, 2011–2015
Figure 4.2	Stage of HIV Infection at Diagnosis for BC by Gender, 2011–2015
Figure 4.3	Stage of HIV Infection at Diagnosis for BC by Age Category, 2011–2015
Figure 4.4	Stage of HIV Infection at Diagnosis for BC by Exposure Category, 2011–2015
Indicator 5	HIV Cascade of Care
Figure 5.1	Estimated Cascade of Care for BC, Year Ending 2016 Q3
Figure 5.2	Estimated Cascade of Care for BC by Gender, Year Ending 2016 Q3
Figure 5.3	Estimated Cascade of Care for BC by Age Category, Year Ending 2016 Q3
Figure 5.4	Estimated Cascade of Care for вс by Мѕм Status, Year Ending 2016 Q3

Figure 5.5	Estimated Cascade of Care for вс by Age Category and Msм Status, Year Ending 2016 Q3
Figure 5.6	Estimated Cascade of Care for BC by PWID Status, Year Ending 2016 Q3
Figure 5.7	Estimated Cascade of Care for вс by Health Authority, Year Ending 2016 Q3
Indicator 6	Programmatic Compliance Score (PCS)
Table 2	Probability of Mortality, Immunologic Failure and Virologic Failure Based on the Programmatic Compliance Score
Figure 6.1	Pcs Components for BC, 2014 Q4-2016 Q3
	Less than 3 CD4 Tests in First Year
	Less than 3 Viral Load Tests in First Year
	Not Having Drug Resistance Testing at Baseline
	Non-Recommended Antiretroviral Therapy Regimen (ART)
	Baseline CD4 < 200 cells/µL
	Not Achieving Viral Suppression at 9 Months
Figure 6.2	Historical Trends for Pcs Score for BC, 2014 Q4–2016 Q3
Indicator 7	New Antiretroviral Therapy Starts in BC
Figure 7	BC-CfE Drug Treatment Program Enrollment: New Antiretroviral Participants for BC, 2014 Q4–2016 Q3
Indicator 8	CD4 Cell Count at ART Initiation
Figure 8	CD4 Cell Count at Art Initiation for BC, 2014 Q4–2016 Q3
Indicator 9	Active and Inactive Drug Treatment Program (DTP) Participants
Table 3	Distribution of People on Art in BC, 2016 Q3
Figure 9	Active and Inactive DTP Participants for BC, 2014 Q4–2016 Q3
Indicator 10	Antiretroviral Adherence
Figure 10	Distribution of Individuals by Adherence Level in 1st Year of Therapy, Based on Pharmacy Refill Compliance for BC, 2014 Q4–2016 Q3
Indicator 11	Resistance Testing and Results
Figure 11	Cumulative Resistance Testing Results by Resistance Category for вс, 2014 Q4-2016 Q3
Indicator 12	AIDS-Defining Illness
Figure 12	AIDS Case Rate and Reports for BC, 2008–2015
Indicator 13	HIV-Related Mortality
Figure 13	HIV-Related Deaths by Year for BC, 2004–2011

# Acknowledgements and Contributions



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

**British Columbia Centre for Excellence in HIV/AIDS (BC-CFE):** The BC-CFE is responsible for the conception, preparation and ongoing review of this quarterly report. The BC-CFE provides the data and outputs for Indicators 5 (HIV Cascade of Care), 6 (Programmatic Compliance Score), 7 (New Antiretroviral Starts), 8 (CD4 Cell Count at ART Initiation), 9 (Active and Inactive Drug Treatment Program Participants), 10 (Antiretroviral Adherence Level), 11 (Resistance Testing Results by Resistance Category), 12 (AIDS-Defining Illness), and 13 (HIV-Related Mortality). The BC-CFE database provides PVL and CD4 cell count testing data, as well as ART use. All PVL measurements in BC are performed at the St Paul's Hospital virology laboratory, thus PVL data capture is 100%. An estimated 80% of all CD4 count measurements performed in the province are captured in the BC-CFE data holdings. The STOP HIV/AIDS Technical Monitoring Committee–BC-CFE is responsible for oversight of the monitoring report. James Nakagawa is responsible for compiling and publishing this report. Lilith Swetland is the editor of this report. Paul Sereda, Dr. Viviane Lima and Nada Gataric perform analysis of Indicators 5–13. This report was conceived and guided by Dr. Julio Montaner.



BC Centre for Disease Control An agency of the Provincial Health Services Authority

**British Columbia Centre for Disease Control (BCCDC):** The BCCDC provides the data and outputs for Indicator 1 (HIV Testing Episodes), Indicator 2 (HIV Testing Rate), Indicator 3 (New HIV Diagnoses), Indicator 4 (Stage of HIV at Diagnosis) and Indicator 12 (AIDS-Defining Illness). The BCCDC is the single provincial agency that centralizes all HIV surveillance through the Public Health Microbiology and Reference Laboratory, which does more than 90% of all HIV screening tests in BC and all confirmatory testing. Olga Mazo, Theodora Consolacion and Dr. Jason Wong are responsible for outputs for Indicators 1–4.

#### **Other Data Sources:**

The above databases were supplemented with:

(I) The BC Vital Statistics database which was used to calculate Indicator 5. The HIV Cascade of Care and Indicator 13. HIV-Related Mortality.

(II) Linkage and preparation of the de-identified individual-level database used for calculating Indicator 5. The HIV Cascade of Care was facilitated by the British Columbia Ministry of Health.

(III) The Statistics Canada database: BC and HIV-positive population counts were acquired through the statistics Canada website to calculate HIV-specific mortality rates for Indicator 13. HIV-Related Mortality.

# Membership of the STOP HIV/AIDS Technical Monitoring Committee–BC-CfE

Dr. Rolando Barrios, *Chair*, BC-CFE Dr. Kate Heath, BC-CFE Dr. Bohdan Nosyk, BC-CFE Dr. Viviane Dias Lima, BC-CFE Irene Day, BC-CFE Dr. Jean Shoveller, BC-CFE Dr. Jason Wong, BCCDC Dr. Mel Krajden, BCCDC Salman Klar, FHA Jennifer May-Hadford, IHA Kari Harder, NHA Dr. Neora Pick, PHSA Dr. Reka Gustafson, VCHA Dr. Melanie Rusch, VIHA

# The Seek and Treat for Optimal Prevention (STOP) HIV/AIDS BC Provincial Program: A Note on Monitoring and Interpreting HIV Indicators

The Seek and Treat for Optimal Prevention (STOP) of HIV/AIDS programme is a provincial initiative to improve HIV diagnosis and care delivery in BC through increased HIV-specific funding to all Health Service Delivery Areas (HSDA'S) across BC. The STOP provincial programme is an expansion of a four-year STOP pilot project which was implemented in two Health Service Delivery Areas in March 2010; the Vancouver HSDA which bears the largest burden of the HIV epidemic in the province and the Northern Interior HSDA which bears a high burden of HIVrelated mortality. The STOP pilot project demonstrated the urgent need for improved efforts in early diagnosis of HIV and timely initiation of antiretroviral therapy (ART) initiation.


The expansion to a province-wide programme was announced on November 30th, 2013 by the BC Ministry of Health with roll out of funding beginning on April 1st, 2013. This funding is intended to be used in the implementation and evaluation of HIV-related diagnosis and care initiatives within individual HA's. Goals of the project include: 1. A reduction in the number of new HIV infections in BC; 2. Improvements in the quality, effectiveness, and reach of HIV prevention services; 3. An increase in early diagnosis of HIV; 4. A reduction in AIDS cases and HIV-related mortality.

The goals of HA-led STOP-funded initiatives are to work toward achieving these goals. To these ends some outcome measures or indicators of progress have been drafted that should be considered in the design and implementation phases of these initiatives.


## **HIV Testing Episodes and Rates**

In this section, the number of HIV test episodes and point of care (POC) HIV tests conducted each quarter in BC is shown. In general terms the goal is to increase the number of tests performed and to maximize testing efficiency. Test episodes are allocated by region according to where the test is performed.


#### Indicator 1. HIV Testing Episodes













1 Data Source: The BC Public Health Microbiology and Reference Laboratory (BCPHMRL) courtesy of the BC Centre for Disease Control (BCCDC). HIV screening tests conducted by the VIHA Laboratory are not included.

*Limitation: Repeat tests in individuals who test using various identifiers may not be identified and these individuals may be counted more than once.* 

2 Testing does not include point of care tests.





Northern Health Vancouver Coastal Health Island Health

0.8 1.1 1.0 1.0

1.2 1.2

8.8 10.5 10.3 11.4 11.9 14.3 15.3 14.4 14.3 16.8 18.3 20.4

1.7 2.0 1.8 1.8 1.8 2.0 2.1 2.0 1.9 2.2 2.1 2.1 2.1 2.6

1.4 1.6 1.4 1.5 1.4 1.6 1.5 1.4

19.8 21.8 21.4 21.9 21.7 24.1


2.6 2.8 2.9 3.1


23.4 22.7

3.2 2.8

1.3 1.3

1.2 1.4








*Testing does not include point of care tests.* 


## New HIV Diagnoses


Trends in HIV diagnoses by gender and exposure category are described. Interpreting HIV diagnoses must be done with consideration that trends are influenced by both changes in testing rate as well as changes in transmission rates. It is important to note that new HIV diagnoses cases and rates are not synonymous with HIV incidence as a person may have become infected with HIV long before they tested positive for HIV. However, as there is no reliable method for measuring HIV incidence, we follow trends in HIV diagnoses.












3 Data Source: BCCDC. When present, "By Provider Address" is graphed as dashed line in same colour.

4 MSM=men who have sex with men; PWID=people who inject drugs; HET=heterosexual. NIR=No identified risk/exposure.




3 Data Source: BCCDC. When present, "By Provider Address" is graphed as dashed line in same colour.

# Stage of HIV Infection at Diagnosis

Classification of stage of HIV infection, in the absence of information regarding recent testing history, is reliant on clinical information available at the time of diagnosis, including first CD4+ cell count and laboratory results suggestive of acute HIV infection (Table 1). The benefits of Treatment as Prevention (TasP) are maximized when antiretroviral therapy (ART) is initiated at high CD4 cell counts. Accordingly, it is preferable that individuals newly diagnosed with HIV be in the early stages of HIV infection (stage 0 or 1) to allow for early ART initiation.

N.B. Interpretation of Stage of HIV Infection at Diagnosis should proceed with caution. Early increases in diagnosis at late stage (i.e., low CD4 counts) may represent a "catching up" of previously missed long term infected individuals rather than a trend toward diagnosis at later stage of infection.

Stage of HIV Infection at Diagnosis




#### Indicator 4. Stage of HIV Infection at Diagnosis

#### Table 1 Staging Classifications of Infection at Time of HIV Diagnosis Based on CDC HIV Surveillance Case Definitions

Stage	Criteria											
0	previous negat	eria met for acute HIV infection, or ive or indeterminate HIV test within st confirmed positive HIV test.										
1		CD4 ≥500										
2a		CD4 350-499										
2b	Stage 0 not met and	CD4 200-349										
3	IIULIIIEL	CD4 <200										
Unknown		No available CD4										
Updated .	Updated 2016 Q1: AIDS diagnosis date is no longer used in this indicator.											

#### Figure 4.2 Stage of HIV Infection at Diagnosis by Gender for BC, 2011–2015 <sup>5</sup>



5 Data Source: BCCDC

Figure 4.1





Figure 4.3 Stage of HIV Infection at Diagnosis by Age Category for BC, 2011–2015 <sup>5</sup>

Figure 4.4 Stage of HIV Infection at Diagnosis by Exposure Category for BC, 2011–2015 <sup>5.6</sup>




5 Data Source: BCCDC

6 MSM=men who have sex with men; PWID=people who inject drugs; HET=heterosexual. NIR=No identified risk/exposure.

# HIV Cascade of Care

#### Indicator 5. HIV Cascade of Care

The success of seek, test, treat and retain (STTR) strategies like STOP is reliant on early diagnosis of HIV, linking newly diagnosed HIV-positive persons with ongoing care, retaining persons in HIV-care; initiating ART based on best evidenced practices and maintaining optimal ART adherence to ensure a suppressed viral load. These stages of HIV-care can be summarized as: 1. HIV diagnosis, 2. Linked to HIV care, 3. Retained in HIV care, 4. On ART, 5. Adherent to ART and 6. Achieving a suppressed VL; collectively, they are referred to as the cascade of care. Attrition between any of these stages of HIV-care means a reduction in the potential of ART as a benefit to the HIV-positive individual and as an HIV transmission prevention method on a population level. Thus, when interpreting trends in the cascade of care, we strive to see increases along each step of the cascade of care (i.e. reduced attrition) with the ultimate goal being 100% within each stage of the cascade. Monitoring the Cascade of Care provides a picture as to where deficiencies lie in the delivery and uptake of HIV-care. In this section we present the cascade of care for the period 2015 Q4–2016 Q3 in BC overall and stratified by sex and age for each Health Authority.



7 Data is for the period 2015 Q4–2016 Q3.


Data Sources:

*i* British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).

*ii* Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

*Limitations:* HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

NB: Transgender have been assigned to their biological sex.



## Figure 5.3 Estimated Cascade of Care for British Columbia by Age Category, Year Ending 2016 Q3 <sup>8</sup>


8 Data is for the period 2015 Q4–2016 Q3.

Data Sources:

*i* British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).

*ii* Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.






9 Data is for the period 2015 Q4-2016 Q3.
 Data Sources:

- *i* British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- *ii* Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.



6

Data Sources:

- British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count). .1
  - Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)). ij

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

Data is for the period 2015 Q4–2016 Q3.





Figure 5.6 Estimated Cascade of Care for British Columbia by PWID Status, Year Ending 2016 Q3 <sup>9</sup>

9 Data is for the period 2015 Q4–2016 Q3.

Data Sources:

- *i* British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- *ii* Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.





-20%

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

Data is for the period 2015 Q4-2016 Q3. 6

Data Sources:

i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).

Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)). ii

# Programmatic Compliance Score Indicator 6. Programmatic Compliance Score (PCS)

The Programmatic Compliance Score (PCS) is a summary measure of risk of future death, immunologic failure and virologic failure from all causes for people who are starting ART for the first time. It is composed of patient- and physician-driven effects. PCs scores range from o-6 with higher scores indicative of poorer health outcomes and greater risk of death. Table 2 provides mortality, immunologic failure and virologic failure probabilities for given PCS scores. We interpret an individual with a PCS≥4 as being 22 times more likely to die, almost 10 times more likely to have immunologic failure and nearly 4 times as likely to demonstrate virologic failure compared to those individuals with a PCS score of o. A detailed description of how the PCS score is calculated and its validation can be found in the technical report. In short, PCS scores are calculated by summing the results (yes=1, no=0) of six un-weighted non-performance indicators based on IAS–USA treatment guidelines:


- having <3 CD4 cell count tests in the first year after starting antiretroviral therapy (ART);
- 2. having <3 plasma viral load (VL) tests in the first year after starting ART;
- 3. not having drug resistance testing done prior to starting ART;
- 4. starting on a non-recommended ART regimen;
- 5. starting therapy with CD4<200 cells/µL; and
- 6. not achieving viral suppression within 9 months since ART initiation.

In this section we provide PCs scores and their components over time for the province of BC. A decline to 0%, (i.e., all individuals having a score of o) is the eventual goal.

Table 2. Probability of Mortality, Immunologic Failure and Virologic Failure based on the Programmatic Compliance Score

Programmatic Compliance Score	Mortality Risk Ratio (95% Confidence Interval)	Immunologic Failure Risk Ratio (95% CI)	Virologic Failure Risk Ratio (95% CI)
0 (Best score)	1 (-)	1 (-)	1 (-)
1	3.81 (1.73-8.42)	1.39 (1.04–1.85)	1.32 (1.05–1.67)
2	7.97 (3.70–17.18)	2.17 (1.54–3.04)	1.86 (1.46–2.38)
3	11.51 (5.28–25.08)	2.93 (1.89–4.54)	2.98 (2.16–4.11)
4 or more (Worst score)	22.37 (10.46–47.84)	9.71 (5.72–16.47)	3.80 (2.52–5.73)

*Reference: Lima VD, Le A, Nosyk B, Barrios R, Yip B, et al. (2012) Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy. PLoS ONE 7(11): e47859. doi:10.1371/journal.pone.0047859* 




10 Data Source: British Columbia Centre for Excellence Drug Treatment Program (DTP) Database. *Limitations:* CD4 cell count capture is approximately 80%.

Each quarter's data is calculated as the sum of the 4 quarters leading up to it. e.g. 2013 Q1 is calculated from 2012 Q2 – 2013 Q1. 11 NB: A score of o is the best score and a score of 4 or more is the worst score.

# Antiretroviral Uptake


In this section we present trends in ART uptake, the number and proportion of new HIV treatment initiations and the number of active and inactive DTP participants. Trends in ART uptake should be interpreted under the consideration of changing BC HIV treatment guidelines. BC HIV treatment guidelines are updated regularly by the BC-CFE Therapeutic Guidelines Committee and reflect those of the International AIDS Society. Most recent changes were made in 2012 and HIV treatment is now recommended for all HIV-positive adults regardless of CD4 cell count; as evidence demonstrates that early initiation of HIV treatment maximizes both the individual's health outcomes as well as the potential of ART as a form of HIV transmission prevention at a population level. As such, trends in the number and proportion of persons on ART and new ART starts (in both naïve and experienced persons) are expected to increase over time at higher CD4 cell counts.

## Indicator 8. CD4 Cell Count at ART Initiation



# Indicator 7. New Antiretroviral Therapy Starts in BC

Figure 7 BC-CfE Drug Treatment Program Enrollment: New ART Participants in BC, 2014 Q4–2016 Q3 <sup>12</sup>




- 12 Data Source: Drug Treatment Program Database Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.
- 13 Data Source: Drug Treatment Program Database Limitations: CD4 cell count data is approximately 80% complete.

## Indicator 9. Active and Inactive DTP Participants

		Fraser	Interior	Island	Northern	Vancouver Coastal	Total BC
Age	< 30	83	21	36	8	134	282
	30-39	265	46	94	48	545	999
	40-49	512	102	218	65	1021	1918
	≥ 50	929	300	537	100	2283	4149
Gender	Male	1391	373	721	142	3508	6135
	Female	398	96	164	79	475	1213
Exposure	MSM	582	153	261	34	1919	2949
	PWID	440	146	278	111	1124	2100
Total		1789	469	885	221	3983	7348

#### Table 3. Distribution of People on ART for BC, 2016 Q3 $^{\rm 14}$



#### 14 Data Source: Drug Treatment Program Database Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.

#### Definition:

2014 2015

'On antiretroviral therapy' defined as being on treatment in the current quarter


2016

15 Active DTP participants: An individual who has had medication prescribed at least once in the preceding quarter. Inactive DTP participants: Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment Program in the last quarter.

# Antiretroviral Adherence Level

In this section we present trends in prescription refill adherence levels for individuals in their first year of treatment. Given that the benefits of ART are compromised in the presence of imperfect ART adherence, we expect to see the proportion of persons on ART achieving near perfect adherence (ie.  $\geq$ 95%) to increase with time. Furthermore, it is important that trends in the proportion of ART users achieving prescription refill adherence of  $\geq$ 95% keep pace with new ART starts and increase among those continuing on ART.






<sup>16</sup> Data Source: Drug Treatment Program Database Limitation: Prescription refill adherence is used as a proxy for patient adherence.

# **Resistance Testing and Results**

## Indicator 11. Resistance Testing and Results

In this section, we present trends in cumulative resistance testing by resistance category: Suppressed (where a DTP participant's viral load is too low to be genotyped); Wild Type (where no HIV treatment resistances were discovered), Never Genotyped, and Resistances to one, two, three, or four HIV treatment classes. Resistance testing prior to ART initiation is recommended in the BC HIV treatment primary care guidelines. Thus, it is expected that trends over time should find all persons enrolled in the DTP to have been genotyped. Trends over time should also show an increase in the proportion of DTP participants achieving a suppressed status and an increase in resistance testing should not lead to an increase in the number of ART resistances occurring.




17 Data Source: Drug Treatment Program Database

Limitation: DTP participants are designated to a HA based on most current residence provided by the participant.

# AIDS-Defining Illness Indicator 12. AIDS-Defining Illness

Improvements in ART and the expansion of ART province-wide has led to very low numbers of recorded AIDS cases across BC. However, interpreting trends in AIDS cases is challenging as AIDS reporting is passive in BC and it is likely that they are under-reported across all Health Authorities. In addition to under-reporting, methods of reporting AIDS cases are inconsistent across HA's and do not truly reflect the current reality of new AIDS diagnoses. Efforts will need to be made to improve under- and inconsistent reporting of AIDS cases across all HA's. The table below shows AIDS cases using three definitions. First, AIDS cases were defined as the number of physician-reported AIDS defining illness (ADI) in a given year. AIDS case reporting is a passive process and physicians can voluntarily report AIDS cases to the BCCDC or DTP. As such, we have plotted both BCCDC reports and DTP reported AIDS cases. We also show the proportion of persons initiating ART with a CD4<200 cells/µL.




18 Data Source: DTP AIDS cases are obtained from the Drug Treatment Program Database; BCCDC AIDS cases are obtained from the BC-CDC; CD4<200 at ART initiation data came from the DTP database. Indicator 12 also reflects information from BC Vital Statistics. As this information is made available to BC-CFE, we use it to inform the development and refinement of this indicator.

Limitation: AIDS case reporting was investigated using 3 definitions: First, using AIDS cases reported in AIDS case report forms from the DTP; Second, using AIDS cases reported via the BCCDC and third, using a CD4 cell count of <200 cells/ $\mu$ L at time of ART initiation using DTP data. AIDS case reporting is passive in BC, thus; AIDS case reporting is not well captured. The DTP sends out AIDS reporting forms to physicians annually. The BCCDC uses DTP AIDS case reports as well as physician AIDS case reports made directly to the BCCDC. Interpreting AIDS case reports should be done with these limitations in mind. AIDS data is updated annually as very few AIDS cases reports are reported in general and trends would be difficult to notice if reported quarterly.

# HIV-Related Mortality

## Indicator 13. HIV-Related Mortality

Evidence indicates that individuals who initiate treatment with recommended ART in a timely fashion may live near normal lifespans. Excess mortality among HIV positive persons is, therefore, an important measure of HIV care with a goal of minimizing HIV-related mortality in British Columbia.



19 Data Source: BC Vital Statistics

Limitation:

1. DTP participants are designated to an HA based on most current residence provided by the participant.

2. Mortality data is updated annually.

3. The most recent available data was used.

#### APPENDICES

Indicator 1	Indicator 1: <b>Test Episodes</b>						2013				2014				2015				2016		
(thousand	s)	Q4	Q1	Q2	Q3																
British Col	lumbia	37.6	42.3	41.5	45.0	46.6	54.8	58.0	55.9	54.6	61.9	66.1	71.2	70.4	77.9	76.9	79.8	80.6	88.7	87.7	83.0
Gender	Female	16.6	18.9	18.9	20.8	21.5	25.7	27.5	26.4	25.6	28.7	31.2	33.7	33.7	37.4	37.3	38.7	38.7	42.3	42.6	40.1
	Male	18.0	20.8	20.1	21.6	22.7	26.2	27.9	26.5	26.2	30.0	31.6	33.8	33.7	37.2	36.7	38.3	39.1	43.3	42.5	40.4
	Other	0.5	0.4	0.3	0.4	0.3	0.3	0.2	0.2	0.2	0.3	0.3	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Age	< 30	13.0	14.0	13.5	14.8	14.7	15.7	16.7	16.8	16.3	17.4	17.6	19.2	18.9	19.7	19.9	21.8	21.8	22.2	22.6	22.8
	30-39	8.7	10.1	9.7	10.2	10.3	12.2	12.7	12.3	11.9	13.9	13.9	14.6	14.0	16.1	16.0	16.6	16.1	18.6	18.3	17.3
	40-49	6.0	6.9	6.8	6.9	7.6	9.0	9.3	8.7	8.5	9.7	10.1	10.5	10.5	11.6	11.4	11.7	11.8	13.3	12.9	11.8
	$\geq 50$	7.0	8.8	9.1	10.5	11.7	15.2	16.9	15.2	15.2	17.8	21.4	23.5	24.0	27.4	26.9	27.0	28.3	31.7	31.6	28.8
POC Tests		2.5	2.3	2.1	2.3	2.2	2.6	2.4	2.7	2.6	3.0	3.0	3.3	2.9	2.9	2.6	2.6	2.6	2.7	2.3	2.2
Fraser Hea	lth	9.0	10.1	10.1	10.8	11.6	13.5	14.0	13.7	12.9	13.6	14.5	14.9	15.1	16.1	15.8	16.8	17.1	18.5	19.2	17.9
Female	4.3	4.7	4.9	5.3	5.7	6.6	6.8	6.8	6.1	6.5	6.9	7.2	7.4	7.5	7.6	8.1	8.1	8.8	9.3	8.5	
Male	4.6	5.3	5.1	5.4	5.7	6.6	7.0	6.7	6.5	6.9	7.1	7.3	7.5	8.1	7.8	8.4	8.6	9.4	9.6	9.1	
Interior H	ealth	4.2	4.1	4.0	4.2	4.2	4.4	4.7	4.6	4.9	5.3	5.5	5.6	5.9	6.6	7.0	7.9	9.1	10.5	9.8	9.0
Female		2.1	2.1	2.0	2.1	2.0	2.1	2.3	2.2	2.4	2.6	2.6	2.7	2.8	3.2	3.4	3.9	4.5	5.1	4.9	4.4
Male		2.0	2.0	1.9	2.0	2.1	2.2	2.3	2.3	2.4	2.6	2.8	2.7	2.9	3.2	3.4	3.8	4.4	5.1	4.8	4.4
Island Hea	lth	3.5	4.0	3.7	3.8	4.0	4.2	4.5	4.3	4.3	4.9	4.8	4.8	4.9	5.9	6.0	6.4	6.6	7.1	7.2	6.5
Female		1.7	1.9	1.8	1.9	2.0	2.1	2.2	2.1	2.1	2.3	2.3	2.4	2.4	2.9	3.0	3.2	3.3	3.5	3.7	3.4
Male		1.7	2.0	1.8	1.8	1.8	2.0	2.1	2.0	1.9	2.2	2.1	2.1	2.1	2.6	2.6	2.8	2.9	3.1	3.2	2.8
Northern l	Health	1.9	2.3	2.2	2.2	2.3	2.7	2.7	2.6	2.6	3.1	3.0	2.9	3.0	3.7	3.2	3.2	3.2	3.7	3.4	3.1
Female		1.0	1.2	1.1	1.2	1.2	1.3	1.4	1.3	1.3	1.6	1.5	1.5	1.5	1.9	1.6	1.6	1.6	1.9	1.7	1.5
Male		0.8	1.1	1.0	1.0	1.1	1.2	1.2	1.1	1.2	1.4	1.3	1.3	1.4	1.6	1.4	1.5	1.4	1.6	1.5	1.4
Vancouver	Vancouver Coastal Health			21.4	24.0	24.5	30.1	32.1	30.7	29.9	35.0	38.4	43.0	41.6	45.5	44.8	45.5	44.6	49.0	48.1	46.5
Female	Female			9.0	10.3	10.6	13.6	14.8	14.0	13.6	15.8	17.9	20.0	19.6	21.8	21.6	21.8	21.2	23.0	23.1	22.2
Male		8.8	10.5	10.3	11.4	11.9	14.3	15.3	14.4	14.3	16.8	18.3	20.4	19.8	21.8	21.4	21.9	21.7	24.1	23.4	22.7

Indicator 2: R	ate of HIV	/ Testing per 100,000		20	09		201	0		2011		2	012		20	13		2014	1	ź	2015	
All British Col	lumbia			2624	1.8		2645.	4	27	714.0		331	8.1		4193	6.4	4	967.4	1	57	35.3	
Fraser Health				225	1.0		2266.	7	23	330.8		279	94.7		3313	5.9	3	590.9	)	40	11.4	
Interior Healt	h			2022	7.5		2072.	6	20	)93.6		218	31.3		2578	3.2	3	000.2	2	40	77.4	
Northern Hea	lth			2292	2.1		2349.	7	24	434.3		291	0.9		3328	3.8	3	825.1	l	43	43.4	
Vancouver Co	oastal Heal	lth		4124	<b>1</b> .7		4139.	9	43	342.3		582	4.7		8114	.3	10	302.2	2	115	77.1	
Island Health				1922	7.0		1920.	0	18	850.8		198	31.8		2151	.0	2	334.8	3	29	40.8	
Gender	Female			2446	5.3		2454.	2	25	523.0		319	5.9		4166	5.3	4	939.1	L	57	63.9	
	Male			2694	<b>1</b> .7		2734.	6	28	309.0		338	3.6		4180	).4	4	951.8	3	56	56.1	
Age	< 30			2794	4.6		2801.	5	28	354.0		323	0.7		3684	.5	4	045.3	3	45	38.8	
0	30-39			5089	9.6		5225.	5	52	251.9		607	2.8		7203	5.7	8	101.6	5	90	07.5	
	40-49			3022	7.6		3025.	3	3	124.1		383	2.7		4933	5.0	5	704.9	)	65	11.0	
	≥ 50			1240	).3		1280.	7	13	395.4		216	8.4		3303	5.0	4	415.0	)	53	55.7	
Indicator 3: N	ew HIV D	liagnoses		2012	2			2013	3			2014	ł			2015	5			2016	5	
		c .	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
British Colum	ibia	By Client Residence	65	70	55	52	60	49	79	80	58	63	75	63	60	64	61	65	49	57	70	75
		By Provider Address	65	70	55	52	60	49	79	80	58	63	75	63	60	64	61	65	49	57	70	75
Gender	Female	7	9	10	5	5	6	12	8	5	13	9	13	9	10	4	12	11	10	11	13	
	Male	58	61	45	47	55	43	67	72	53	49	65	50	51	54	57	53	38	47	59	60	
Age		< 30	18	18	14	9	18	9	17	23	15	17	15	13	18	14	14	21	13	19	15	20
0		30-39	13	16	17	11	10	16	25	18	11	17	21	25	15	15	17	17	8	19	13	22
		40-49	19	20	11	19	19	12	14	21	20	14	14	7	13	11	19	10	11	11	13	11
		≥ 50	15	16	13	13	13	12	23	18	12	15	25	18	14	24	11	17	17	8	29	21
Exposure		MSM	38	42	34	37	36	27	44	45	38	35	46	34	36	37	38	36	25	27		
-		PWID	3	14	7	2	6	4	7	5	9	10	5	3	8	4	4	6	3	1		
		HET	21	14	12	11	15	15	21	24	9	16	19	20	10	17	14	19	17	11		
		Other	3	0	1	0	1	0	1	5	0	0	1	4	2	2	0	1	0	1		
		NIR/Unknown	0	0	1	2	2	3	6	1	2	2	4	2	4	4	5	3	4	17		
Fraser Health		By Client Residence	9	11	10	10	14	8	14	23	19	15	11	16	17	18	17	15	12	19	20	17
		By Provider Address	8	10	5	7	8	9	8	14	15	11	10	12	13	11	11	15	14	17	15	15
Interior Healt	h	By Client Residence	3	5	5	0	2	1	4	4	4	3	4	4	6	5	1	7	6	6	2	4
		By Provider Address	3	5	5	0	2	1	5	4	4	3	2	4	5	5	1	7	6	6	2	3
Island Health		By Client Residence	7	6	3	5	12	4	9	10	7	6	4	7	8	3	7	8	6	7	11	4
By Provider Address		6	3	3	5	12	5	9	10	7	6	4	8	8	3	7	6	5	7	9	3	
Northern Hea	lth	By Client Residence	5	5	4	3	0	3	8	3	3	2	5	4	2	1	2	2	1	2	4	4
		, By Provider Address	6	5	4	3	0	3	8	3	3	2	5	3	2	1	2	2	1	3	4	4
Vancouver Coastal By Client Residence			41	43	33	33	32	31	44	40	25	37	49	32	27	37	34	33	24	23	33	45
Health	42	47	38	37	38	31	49	49	29	41	54	36	32	44	40	35	23	24	40	50		
		By Provider Address																				

#### Indicator 4: Stage of HIV Infection at Baseline

	British Columbia Female				2			N	Male				< 30	) yea	rs			30-3	9 yea	ars			40-4	9 yea	ars					
	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15
Stage 0	64	53	49	64	51	3	6	3	5	9	61	47	45	59	42	14	18	19	28	14	26	18	15	18	16	19	10	10	7	6
1	56	51	58	55	50	8	7	9	13	8	47	43	49	42	42	15	12	22	12	22	21	14	19	18	10	9	16	7	10	7
2a	43	28	46	33	21	8	5	6	4	2	35	23	40	29	19	11	4	12	5	7	14	4	14	7	3	13	11	10	8	5
2b	47	32	36	29	36	10	6	5	5	7	37	26	31	23	28	6	7	4	4	6	10	7	12	7	11	17	10	10	8	8
3	56	57	65	44	49	11	5	7	10	7	45	52	58	34	42	3	7	4	4	5	13	11	10	11	7	20	15	25	13	13
Unknown	22	15	11	35	31	3	1	1	8	5	18	14	10	27	26	5	7	0	7	4	8	3	2	12	11	4	2	3	9	10
Total	288	236	265	260	238	43	30	31	45	38	243	205	233	214	199	54	55	61	60	58	92	57	72	73	58	82	64	65	55	49

	$\geq$ 50 years					Ν	1SM			ŀ	Ieter	osez	cual			Р	WID	)		Ot	her	Expo	osure	2	N	IR/U	Jnkn	own		
	'11	'12	13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15	'11	'12	'13	'14	'15
Stage 0	5	7	5	11	15	52	42	36	54	34	5	4	7	4	4	7	7	4	4	13	0	0	1	1	0	0	0	1	1	0
1	11	9	10	15	11	34	33	36	30	36	8	6	6	10	1	13	11	13	13	9	1	1	0	1	1	0	0	3	1	3
2a	5	9	10	13	6	28	17	30	18	14	6	6	6	1	1	7	5	7	10	4	2	0	2	0	1	0	0	1	4	1
2b	14	8	10	10	11	24	16	24	13	21	3	7	0	4	4	19	8	9	10	9	1	0	1	1	1	0	1	2	1	1
3	20	24	26	16	24	20	30	24	16	16	7	5	5	4	5	27	20	30	18	22	2	0	1	3	0	0	2	5	3	6
Unknown	5	3	6	7	6	12	10	4	19	14	5	1	1	3	2	2	1	5	10	10	1	1	1	1	0	2	2	0	2	5
Total	60	60	67	72	73	170	148	154	150	135	34	29	25	26	17	75	52	68	65	67	7	2	6	7	3	2	5	12	12	16

Indicator 5: HI	V Cascade of (	Care	Diagnosed	Linked	Retained	On ARVs	Adherent	Suppressed
British Columb	oia		10201	9368	7744	7236	6673	5790
Gender	Men		8369	7744	6414	6023	5613	4929
	Women		1833	1624	1330	1213	1060	861
Age Category	< 30		502	345	279	254	213	169
	30-39		1342	1231	1000	920	796	683
	40-49		2558	2385	1950	1813	1648	1405
	≥ 50		5791	5408	4515	4249	4016	3533
MSM Status	MSM		3443	3376	3048	2884	2701	2450
	Non-MSM		2853	2782	2500	2331	2089	1685
	Unknown		3905	3211	2196	2021	1883	1655
Age Category	MSM	< 30	139	126	110	100	85	70
and MSM State	18	30-39	427	411	340	319	280	256
		40-49	721	707	636	598	548	495
		≥ 50	2156	2131	1962	1867	1788	1629
	Non-MSM	< 30	49	49	35	31	23	16
		30-39	368	356	321	292	242	185
		40-49	840	818	716	667	587	461
		≥ 50	1596	1559	1428	1341	1237	1023
	Unknown	< 30	314	170	134	123	105	83
		30-39	547	464	339	309	274	242
		40-49	997	859	598	548	513	449
		≥ 50	2039	1718	1125	1041	991	881
PWID Status	PWID		2530	2473	2254	2112	1882	1506
	Non-PWID		4684	4593	4135	3908	3664	3276
	Unknown		2988	2302	1354	1216	1127	1008
Health	Fraser Health	ı	2152	2072	1844	1756	1600	1388
Authority	Interior Heal	th	617	603	498	467	430	345
	Island Health	ı	1037	1005	918	860	790	658
Northern Health			304	284	244	223	191	142
Vancouver Coastal			4796	4647	4112	3929	3662	3257
	Health							

Indicator 6: Programma	tic		2015					2016		
Compliance Score (PCS)		Q4	Q1		Q2	Q3	Q4	Q1	Q2	Q3
< 3 CD4 Tests		.1%	19.3%	16	5.1%	14.9%	17.7%	16.0%	16.4%	19.3%
< 3 Viral Load Tests		5.9%	7.3%		5.6%	6.7%	7.5%	7.8%	9.0%	10.0%
No Baseline Genotype		2.2%	3.6%		1.6%	3.5%	4.0%	4.2%	4.3%	5.6%
Baseline CD4 < 200 cells/		1.2%	23.0%		1.6%	20.6%	23.0%	23.5%	26.2%	26.2%
Non-Recommended AR	•	3.7%	2.2%		1.7%	1.6%	3.4%	7.2%	8.3%	10.3%
Non Viral Suppression at		).6%	27.7%		5.6%	24.4%	24.5%	25.2%	28.7%	27.4%
PCS Score: 0		159	171	20	178	172	163	143	136	127
PCS Score: 1		111	111		102	88	94	96	114	113
PCS Score: 2		62	46		46	33	38	44	44	49
PCS Score: 3		19	22		17	16	20	19	22	23
PCS Score: 4 or more		5	7		5	6	7	4	8	9
Total (n=)		356	357		348	315	322	306	324	321
Indicator 7: New DTP A	RV Participants									
First Starts		78	88		97	75	72	57	74	93
Experienced Starts		113	134		125	122	141	118	129	130
Indicator 8: CD4 Cell Co	unt Initiation for A	RV-Na	ive DTP Pa	rticipan	ts					
CD4 ≥ 500		29	32	-	34	29	28	14	32	29
CD4 350-499		14	13		12	9	10	15	14	19
CD4 200-349		15	22		21	14	13	11	11	18
CD4 50-199		12	13		17	11	10	11	12	21
CD4 < 50		6	4		11	10	6	4	4	3
CD4 MED		390	388		340	360	401	378	479	370
Total (n=)		76	84		95	73	67	55	73	90
Indicator 9: Active and I	nactive DTP Partici	nants								
Active DTP Participants		5992	7056	5	7131	7172	7236	7240	7289	7348
Inactive DTP Participant		153	1158		1155	1168	1164	1193	1206	1249
	1 4 11									
Indicator 10: Antiretrovi $\geq 95\%$	ral Adherence	81	79		74	73	68	70	81	74
		81 14	79 14				68 12		81 17	74 15
80% to < 95% 40% to < 80%		14 6	14		20 8	16 12	12	21 12	8	6
40% t0 < 80%		0	13		8 0	12	2	2	8 3	3
< 40% Total (n=)		101	107		102	102	85	105	109	98
i otal (II–)		101	107		102	102	85	105	109	20
Indicator 11: Resistance	•									
Suppressed		1919	5244	5	5205	5081	5093	5463	5361	5236
Wild Type		623	694		655	765	656	586	532	605
Never Genotyped		33	40		41	41	35	28	25	24
1-Class		141	151		143	137	113	110	108	109
2-Class		27	31		25	31	22	15	15	14
3-Class		3	8		8	7	2	3	2	3
4-Class	_	0	0		0	0	1	0	0	0
Total (n=)	5	5746	6168	6	6077	6062	5922	6205	6043	5991
Indicator 12: AIDS-Defin	ning Illness		2008	2009	2010	201	2012	2013	2014	2015
CD4 < 200 at	Cases		193	155	138	3 11		90	84	84
ART initiation	Rate per 100,000		4.4	3.5	3.1		.6 2.1	2.0	1.8	1.8
AIDS Cases	Cases		131	110	108	8 8	37 75	83	82	71
(DTP Reports)	Rate per 100,000		3.0	2.5	2.4		.9 1.7	1.8	1.8	1.5
AIDS Cases	Cases		143	127	113	3 9	95 76	73	70	-
(BCCDC Reports)	Rate per 100,000		3.3	2.9	2.5	5 2	.1 1.7	1.6	1.5	-
Indicator 13: HIV-Relate	d Mortality		2004	2005	2006	5 200	07 2008	2009	2010	2011
British Columbia			105	146	142			63	54	59
Per 100 HIV+ Population	ı		1.03	1.40	1.34			0.56	0.47	0.50
Per 100,000 Population	-		2.50	3.43	3.29			1.41	1.19	1.29
				0.10	5.23		1.50		1.17	1.27